Sage Therapeutics, Inc. (NASDAQ:SAGE)‘s stock had its “buy” rating reissued by J P Morgan Chase & Co in a note issued to investors on Wednesday.

SAGE has been the topic of a number of other research reports. Stifel Nicolaus began coverage on shares of Sage Therapeutics in a research report on Monday, November 14th. They issued a “buy” rating and a $90.00 target price on the stock. Leerink Swann restated an “outperform” rating and issued a $68.00 target price on shares of Sage Therapeutics in a research report on Tuesday, October 4th. Raymond James Financial, Inc. began coverage on shares of Sage Therapeutics in a research report on Tuesday, September 13th. They issued an “outperform” rating and a $75.00 target price on the stock. Cowen and Company restated a “buy” rating on shares of Sage Therapeutics in a research report on Monday, September 19th. Finally, Canaccord Genuity restated a “buy” rating and issued a $110.00 target price on shares of Sage Therapeutics in a research report on Tuesday, December 6th. One analyst has rated the stock with a sell rating, one has issued a hold rating, ten have issued a buy rating and one has assigned a strong buy rating to the company. The company has an average rating of “Buy” and an average price target of $70.46.

Analyst Recommendations for Sage Therapeutics (NASDAQ:SAGE)

Shares of Sage Therapeutics (NASDAQ:SAGE) opened at 53.88 on Wednesday. The company has a 50 day moving average of $50.09 and a 200-day moving average of $43.28. The company’s market cap is $2.00 billion. Sage Therapeutics has a 52-week low of $26.28 and a 52-week high of $56.45.

Sage Therapeutics (NASDAQ:SAGE) last issued its earnings results on Thursday, November 3rd. The biopharmaceutical company reported ($1.15) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.10) by $0.05. Analysts forecast that Sage Therapeutics will post ($4.36) EPS for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: “Sage Therapeutics, Inc. (SAGE) Rating Reiterated by J P Morgan Chase & Co” was reported by Daily Political and is the sole property of of Daily Political. If you are viewing this piece on another site, it was stolen and republished in violation of international trademark and copyright law. The correct version of this piece can be viewed at http://www.dailypolitical.com/2017/01/13/sage-therapeutics-inc-sage-rating-reiterated-by-j-p-morgan-chase-co.html.

In related news, CFO Kimi Iguchi sold 1,500 shares of Sage Therapeutics stock in a transaction on Friday, November 11th. The shares were sold at an average price of $50.59, for a total transaction of $75,885.00. Following the completion of the transaction, the chief financial officer now owns 79,739 shares of the company’s stock, valued at $4,033,996.01. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Corporate insiders own 5.60% of the company’s stock.

A number of large investors have recently bought and sold shares of the stock. RS Investment Management Co. LLC increased its stake in Sage Therapeutics by 1.8% in the second quarter. RS Investment Management Co. LLC now owns 586,826 shares of the biopharmaceutical company’s stock valued at $17,681,000 after buying an additional 10,435 shares during the period. Candriam Luxembourg S.C.A. increased its stake in Sage Therapeutics by 7.2% in the second quarter. Candriam Luxembourg S.C.A. now owns 74,000 shares of the biopharmaceutical company’s stock valued at $2,230,000 after buying an additional 5,000 shares during the period. Alps Advisors Inc. increased its stake in Sage Therapeutics by 25.1% in the second quarter. Alps Advisors Inc. now owns 45,044 shares of the biopharmaceutical company’s stock valued at $1,357,000 after buying an additional 9,036 shares during the period. Bank of New York Mellon Corp increased its stake in Sage Therapeutics by 13.0% in the second quarter. Bank of New York Mellon Corp now owns 104,010 shares of the biopharmaceutical company’s stock valued at $3,134,000 after buying an additional 11,978 shares during the period. Finally, California State Teachers Retirement System increased its stake in Sage Therapeutics by 68.3% in the second quarter. California State Teachers Retirement System now owns 55,542 shares of the biopharmaceutical company’s stock valued at $1,673,000 after buying an additional 22,531 shares during the period.

About Sage Therapeutics

SAGE Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in developing and commercializing medicines to treat central nervous system (CNS) disorders. Its lead product candidate, SAGE-547 is an intravenous formulation of allopregnanolone, a neurosteroid that acts as a synaptic and extrasynaptic modulator of the GABAA receptor.

5 Day Chart for NASDAQ:SAGE

Receive News & Ratings for Sage Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sage Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.